15:23:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-07-25 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-11 Årsstämma 2024
2024-02-22 Halvårsutdelning AZN 20.65
2024-02-08 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-10 Halvårsutdelning AZN 9.64
2023-07-28 Kvartalsrapport 2023-Q2
2023-04-27 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-23 Halvårsutdelning AZN 20.69
2023-02-09 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Halvårsutdelning AZN 9.49
2022-07-29 Kvartalsrapport 2022-Q2
2022-04-29 Kvartalsrapport 2022-Q1
2022-04-29 Årsstämma 2022
2022-02-24 Halvårsutdelning AZN 18
2022-02-10 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-12 Halvårsutdelning AZN 7.72
2021-07-29 Kvartalsrapport 2021-Q2
2021-05-11 Årsstämma 2021
2021-04-30 Kvartalsrapport 2021-Q1
2021-02-25 Halvårsutdelning AZN 15.76
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-13 Halvårsutdelning AZN 7.87
2020-07-30 Kvartalsrapport 2020-Q2
2020-04-29 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Halvårsutdelning AZN 18.32
2020-02-14 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-08 Halvårsutdelning AZN 8.49
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-26 Kvartalsrapport 2019-Q1
2019-04-26 Årsstämma 2019
2019-02-28 Halvårsutdelning AZN 17.46
2019-02-14 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-09 Halvårsutdelning AZN 7.92
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-18 Kvartalsrapport 2018-Q1
2018-05-18 Årsstämma 2018
2018-02-15 Halvårsutdelning AZN 14.97
2018-02-02 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-10 Halvårsutdelning AZN 7.4
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-16 Halvårsutdelning AZN 16.57
2017-02-02 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-11 Halvårsutdelning AZN 7.81
2016-07-28 Kvartalsrapport 2016-Q2
2016-04-29 Kvartalsrapport 2016-Q1
2016-04-29 Årsstämma 2016
2016-02-18 Halvårsutdelning AZN 16.26
2016-02-04 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-13 Halvårsutdelning AZN 7.71
2015-07-30 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-24 Årsstämma 2015
2015-02-19 Halvårsutdelning AZN 15.62
2015-02-05 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-13 Halvårsutdelning AZN 6.2
2014-07-31 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-24 Årsstämma 2014
2014-02-19 Halvårsutdelning AZN 12.41
2014-02-06 Bokslutskommuniké 2013
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-14 Halvårsutdelning AZN 5.92
2013-08-01 Kvartalsrapport 2013-Q2
2013-08-01 Analytiker möte 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-13 Halvårsutdelning AZN 12.08
2013-01-31 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-10-25 Analytiker möte 2012
2012-08-08 Halvårsutdelning AZN 6.26
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-26 Årsstämma 2012
2012-02-15 Halvårsutdelning AZN 13.21
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-03 Halvårsutdelning AZN 5.33
2011-07-28 Kvartalsrapport 2011-Q2
2011-04-28 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-02 Halvårsutdelning AZN 11.99
2011-01-27 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-04 Halvårsutdelning AZN 5.12
2010-07-29 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-03 Halvårsutdelning AZN 12.43
2010-01-28 Bokslutskommuniké 2009
2009-10-29 Kvartalsrapport 2009-Q3
2009-08-05 Halvårsutdelning AZN 4.41
2009-07-30 Kvartalsrapport 2009-Q2
2009-04-30 Kvartalsrapport 2009-Q1
2009-04-30 Årsstämma 1
2009-02-04 Halvårsutdelning AZN 12.02
2008-08-06 Halvårsutdelning AZN 3.34
2008-02-06 Halvårsutdelning AZN 8.61
2007-08-08 Halvårsutdelning AZN 3.49
2007-02-07 Halvårsutdelning AZN 8.6
2006-08-09 Halvårsutdelning AZN 3.6
2006-02-08 Halvårsutdelning AZN 7.02
2005-08-10 Halvårsutdelning AZN 2.99
2005-02-09 Halvårsutdelning AZN 4.497
2004-08-11 Halvårsutdelning AZN 2.2
2004-02-18 Halvårsutdelning AZN 3.91
2003-08-20 Halvårsutdelning AZN 2.07
2003-02-19 Halvårsutdelning AZN 3.99
2002-08-21 Halvårsutdelning AZN 2.21
2002-02-20 Halvårsutdelning AZN 5.01
2001-08-22 Halvårsutdelning AZN 2.44
2001-02-21 Halvårsutdelning AZN 4.49
2000-09-04 Halvårsutdelning AZN 2.1
2000-03-08 Halvårsutdelning AZN 4.01
1999-09-06 Halvårsutdelning AZN 1.89
1999-04-01 Split AZN 1:0.5045
1997-05-26 Split AZN 1:2
1993-06-14 Split AZN 1:5
1987-06-04 Split AZN 1:2

Beskrivning

LandStorbritannien
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AstraZeneca är ett globalt läkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamt inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.
2021-09-02 08:02:10

Enhertu demonstrates transformative progression-free survival in HER2-positive metastatic breast cancer; data in lung and gastric cancers show strong efficacy across HER2-targetable tumours

Multiple trials reinforce the efficacy of Imfinzi combinations, including with novel immunotherapies, for lung cancer patients across settings

AstraZeneca will present new data across its diverse portfolio of cancer medicines at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Congress 2021.

A total of 14 approved and potential new medicines from AstraZeneca will be featured across more than 100 abstracts at the two meetings. There will be five oral presentations including one Presidential Symposium at WCLC, hosted by the IASLC between 8 and 14 September. A total of 20 oral presentations including one Presidential Symposium will be featured at ESMO between 16 and 21 September.

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: "Imfinzi and Tagrisso have redefined outcomes for patients with lung cancer, becoming the established standards of care around the world in certain settings. Our data at WCLC and ESMO illustrate our commitment to building on the benefits of these medicines with novel combinations to extend them to more patients. Our data will also showcase the real-world impact of these medicines in clinical practice."

Susan Galbraith, Executive Vice President, Oncology R&D said: "The DESTINY-Breast03 data at ESMO will demonstrate the potential for Enhertu to transform the treatment of HER2-positive metastatic breast cancer with a safety profile that supports the potential for Enhertu in early-stage disease. Additionally, the data from COAST will support our aim to extend the benefit of Imfinzi in unresectable, Stage III non-small cell lung cancer by combining it with potential first-in-class immunotherapies. Also, new data on Lynparza will answer critical questions about retreatment with a PARP inhibitor in resistant disease."

Leading in lung cancer with established standards of care and novel combinations

A Presidential Symposium will present results from the final analysis of the POSEIDON Phase III trial at WCLC showing a significant, clinically meaningful survival benefit for the combination of Imfinzi (durvalumab), tremelimumab and chemotherapy in metastatic non-small cell lung cancer (NSCLC).

A late-breaking presentation at ESMO will feature three-year overall survival (OS) data from the CASPIAN Phase III trial of Imfinzi in extensive-stage small cell lung cancer (ES-SCLC), the longest reported to date for a Phase III trial of chemotherapy and PD-1/PD-L1 immunotherapy in this disease setting. Imfinzi is the only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies in ES-SCLC.

In another late-breaking presentation at ESMO, the COAST Phase II trial will highlight progression-free survival (PFS) results for novel Imfinzi combinations with potential new medicines including oleclumab, an anti-CD73 monoclonal antibody, and monalizumab, an anti-NKG2A monoclonal antibody, in unresectable, Stage III NSCLC, building on the PACIFIC Phase III trial results that established Imfinzi as the standard of care in this setting.

Data at ESMO will showcase research into combatting resistant disease, including interim results from the ORCHARD Phase II trial studying the combination of Tagrisso (osimertinib) and savolitinib, an oral, potent and highly selective MET tyrosine kinase inhibitor, in patients with advanced EGFR-mutated (EGFRm) NSCLC with MET alterations whose disease progressed on 1st-line Tagrisso.

Real-world data will provide new compelling evidence for the efficacy and safety profiles of Imfinzi and Tagrisso in NSCLC. At ESMO, PFS and tolerability data will be shared from the PACIFIC-R global observational study of patients with unresectable, Stage III NSCLC treated with Imfinzi after chemoradiation therapy. At WCLC, an interim analysis from the US cohort of a global prospective study will reinforce the efficacy of 1st-line Tagrisso in a real-world population of patients with EGFRm NSCLC.

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs)

At ESMO, a Presidential Symposium will present the results from the DESTINY-Breast03 Phase III trial demonstrating the potentially transformative impact of Enhertu (trastuzumab deruxtecan) for patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. DESTINY-Breast03 is the first global Phase III trial of Enhertu against an active control. In August 2021 (https://www.astrazeneca.com/media-centre/press-releases/2021/enhertu-head-to-head-trial-meets-primary-endpoint.html), the Independent Data Monitoring Committee recommended unblinding the trial based on a planned interim analysis showing a highly statistically significant and clinically meaningful improvement in the primary endpoint of PFS versus trastuzumab emtansine (T-DM1).

Also at ESMO, data will include updated OS data from the DESTINY-Breast01 Phase II trial in HER2-positive metastatic breast cancer and late-breaking results from the DESTINY-Gastric02 Phase II trial in HER2-positive metastatic gastric cancer. A late-breaking presentation will feature primary analysis results from the HER2-mutant cohort of the DESTINY-Lung01 Phase II trial investigating Enhertu in patients with HER2-mutated metastatic NSCLC who have progressed following one or more systemic therapies, a setting where there are currently no approved HER2-directed treatments.

Updated data from the advanced/metastatic NSCLC cohort in the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan (Dato-DXd) will be presented at WCLC in a mini-oral presentation, and new NSCLC sub-analysis data will be shared in a late-breaking presentation at ESMO highlighting clinical activity in patients whose tumours have actionable genomic alterations. There are currently no TROP2-directed medicines approved for NSCLC, a setting where Dato-DXd has shown promising results in Phase I trials.

Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies

At ESMO, late-breaking data will be presented from the OReO/ENGOT Ov-38 Phase IIIb trial testing maintenance retreatment with Lynparza (olaparib) in patients with platinum-sensitive, relapsed epithelial ovarian cancer. OReO is the first Phase III trial to evaluate retreatment with a PARP inhibitor in resistant disease. Another presentation will feature subgroup analyses and updated safety data from the POLO Phase III trial of Lynparza in germline BRCA-mutated metastatic pancreatic cancer, a disease in which no other PARP inhibitor is approved.

An oral presentation will share interim data from an externally sponsored Phase II trial with ceralasertib, an ataxia telangiectasia and rad3-related (ATR) kinase inhibitor, testing anti-tumour activity in patients with ARID1A-deficient and -intact solid tumours.

Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with MSD (Merck & Co., Inc. in the US and Canada) to develop and commercialise Lynparza; with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to develop and commercialise Enhertu and Dato-DXd, and with HUTCHMED to develop and commercialise savolitinib. AstraZeneca obtained full oncology rights to monalizumab from Innate Pharma in October 2018 through a co-development and commercialisation agreement initiated in 2015.

AstraZeneca to host virtual event on 15 September: "Spotting cancer before it has a chance: Can screening become universal?

To highlight diverse viewpoints on universal cancer screening, the Company will host a virtual event in collaboration with the European Alliance for Personalised Medicine on 15 September, 14:00 CEST. The event will bring together experts across disciplines to discuss the future of cancer screening and the barriers that persist to making screening universal. Registration (https://www.astrazenecaevents.com/d/gmqwpn/) for the event is open to the public.

Key AstraZeneca presentations during IASLC WCLC 2021[1]

Lead Abstract Presentation details
author title
Immuno
-Oncology
Garassino, Durvalumab ± Abstract #MA16.06Mini Oral Session: MA16 - SCLC:
MC Tremelimumab New Targets, Biomarkers, and Systemic Therapies13
+ Platinum September 202120:35 - 20:40 MDT14 September
-Etoposide in 20213:35 - 3:40 BST
1L ES-SCLC:
Exploratory
Analysis of
HLA Genotype
and Survival
in CASPIAN
Johnson, Durvalumab ± Abstract #PL02.01Plenary: PL02 - Plenary 2:
ML Tremelimumab Presidential Symposium9 September 20216:30 - 6:40
+ Chemotherapy MDT13:30 - 13:40 BST
as First-line
Treatment for
mNSCLC:
Results from
the Phase 3
POSEIDON
Study
Tumour
drivers
and
resistance
Blakely, A Phase II Abstract #P26.02Posters: P26 - Locally Advanced Non
CM Trial of -Small Cell Lung Cancer - EGFR Targeted Therapy8
Neoadjuvant September 2021
Osimertinib
for
Surgically
Resectable
EGFR-Mutant
Non-Small
Cell Lung
Cancer:
Updated
Results
Nieva, J Real-World Abstract #P48.17Posters: P48 - Novel Therapeutics
Study of and Targeted Therapies - EGFR8 September 2021
Patients With
EGFR Mutated
Locally
Advanced or
Metastatic
Non-Small
Cell Lung
Cancer
Treated With
First-Line
Osimertinib
Sequist, COMPEL: Abstract #P47.11Posters: P47 - Novel Therapeutics
LV Chemotherapy and Targeted Therapies - Clinical Trial in
With/Without Progress8 September 2021
Osimertinib
in Patients
With EGFRm
Advanced
NSCLC and
Progression
on First-Line
Osimertinib
Antibody
drug
conjugates
Borghaei, TROPION Abstract #P47.06Posters: P47 - Novel Therapeutics
H -Lung04: and Targeted Therapies - Clinical Trial in
Datopotamab Progress8 September 2021
Deruxtecan
(Dato-DXd)
Plus
Durvalumab
and Platinum
-Based
Chemotherapy
in Advanced
NSCLC
Garon, EB TROPION Abstract #MA03.02Mini Oral Session: MA03 -
-PanTumor01: Biomarkers for Immunotherapy: Are All Relevant?8
Updated September 202110:50 - 10:55 MDT17:50 - 17:55 BST
Results From
the NSCLC
Cohort of the
Phase 1 Study
of
Datopotamab
Deruxtecan in
Solid Tumors
Johnson, A Phase 2 Abstract: #P47.05 Posters: P47 - Novel Therapeutics
ML Study of and Targeted Therapies - Clinical Trial in
Datopotamab Progress8 September 2021
Deruxtecan
(Dato-DXd) in
Advanced
NSCLC With
Actionable
Genomic
Alterations
(TROPION
-Lung05)
Levy, B TROPION Abstract #P47.04Posters: P47 - Novel Therapeutics
-Lung02: and Targeted Therapies - Clinical Trial in
Datopotamab Progress8 September 2021
Deruxtecan
(Dato-DXd)
Plus
Pembrolizumab
and Platinum
-Based
Chemotherapy
in Advanced
NSCLC

[1] 22 abstracts at IASLC WCLC 2021 will feature AstraZeneca medicines and pipeline molecules.

Key AstraZeneca presentations during ESMO Congress 2021

Lead Abstract title Presentation details
author
Immuno
-Oncology
Girard, N PACIFIC-R Real Abstract #1171MOMini Oral session - Non
-World Study: -metastatic NSCLC and other thoracic
Treatment malignancies18 September 202117:55 - 18:00
Duration and CEST16:55 - 17:00 BST
Interim Analysis
of Progression
-Free Survival in
Unresectable
Stage III NSCLC
Patients Treated
with Durvalumab
After
Chemoradiotherapy
Martinez COAST: an open Abstract #LBA42Proffered Paper session - Non
-Marti, A -label, phase 2, -metastatic NSCLC and other thoracic
multidrug malignancies17 September 202114:20 - 14:30
platform study of CEST13:20 - 13:30 BST
durvalumab alone
or in combination
with novel agents
in patients with
unresectable,
Stage III NSCLC
Paz-Ares, Durvalumab ± Abstract #LBA61Mini Oral session - Non
L tremelimumab + -metastatic NSCLC and other thoracic
platinum malignancies18 September 202118:10 - 18:15
-etoposide in CEST17:10 - 17:15 BST
first-line
extensive-stage
SCLC (ES-SCLC):
36-month overall
survival from the
Phase 3 CASPIAN
study
Tumour
drivers
and
resistance
Cheema, P Modelling long Abstract #1165PePoster
-term survival
outcomes in
patients with
stage (stg)
IB-IIIA EGFR
-mutated NSCLC
from the ADAURA
trial
Hamilton, CAPItello-292: a Abstract #338TiPePoster
E phase 1b/3 study
of capivasertib,
palbociclib and
fulvestrant
versus placebo,
palbociclib and
fulvestrant in
HR+/HER2-advanced
breast cancer
Yu, H ORCHARD Abstract #1239PePoster
osimertinib +
savolitinib
interim analysis:
A biomarker
-directed Phase
II platform study
in patients (pts)
with advanced non
-small cell lung
cancer (NSCLC)
whose disease has
progressed on
first-line (1L)
osimertinib
Antibody
drug
conjugates
Saura, C Trastuzumab Abstract #279PePoster
Deruxtecan (T
-DXd) in Patients
with HER2
-Positive
Metastatic Breast
Cancer (MBC):
Updated Survival
Results from a
Phase 2 Trial
(DESTINY
-Breast01)
Cortés, J Trastuzumab Abstract #LBA1Presidential symposium 118
Deruxtecan (T September 202115:05 - 15:20 CEST14:05 - 14:20
-DXd) vs BST
Trastuzumab
Emtansine (T-DM1)
in Patients (Pts)
With HER2+
Metastatic Breast
Cancer (mBC):
Results of the
Randomized Phase
3 DESTINY
-Breast03 Study
Van Primary Analysis Abstract #LBA55Mini oral session -
Cutsem, E of a Phase 2 Gastrointestinal tumours, non-colorectal17
Single-Arm Trial September 202117:45 - 17:50 CEST16:45 - 16:50
of Trastuzumab BST
Deruxtecan (T
-DXd) in Western
Patients (Pts)
With HER2
-Positive (HER2+)
Unresectable or
Metastatic
Gastric or
Gastroesophageal
Junction (GEJ)
Cancer Who
Progressed on or
After a
Trastuzumab
-containing
Regimen
Li, BT Primary Data from Abstract #LBA45Proffered Paper session - NSCLC,
DESTINY-Lung01: A metastatic 118 September 202114:00 - 14:10
Phase 2 Trial of CEST13:00 - 13:10 BST
Trastuzumab
Deruxtecan (T
-DXd) in Patients
(Pts) With HER2
-Mutated (HER2m)
Metastatic
Non-Small Cell
Lung Cancer
(NSCLC)
Garon, EB Efficacy of Abstract #LBA49Mini oral session - NSCLC,
datopotamab metastatic 19 September 202117:30 - 17:35
deruxtecan (Dato CEST16:30 - 16:35 BST
-DXd) in patients
(pts) with
advanced/metastati
c (adv/met) non
-small cell lung
cancer (NSCLC)
and actionable
genomic
alterations
(AGAs):
preliminary
results from the
phase 1 TROPION
-PanTumor01 study
DNA damage
response
Pujade Maintenance Abstract #LBA33Proffered Paper session -
-Lauraine, olaparib Gynaecological cancers17 September 202114:20 -
E rechallenge in 14:30 CEST13:20 - 13:30 BST
patients (pts)
with ovarian
carcinoma (OC)
previously
treated with a
PARP inhibitor
(PARPi): Phase
IIIb OReO/ENGOT
Ov-38 trial
Aggarwal, Interim results Abstract #512OProffered Paper session -
R from a phase 2 Developmental therapeutics17 September
study of the ATR 202113:40 - 13:50 CEST
inhibitor 12:40 - 12:50 BST
ceralasertib in
ARID1A-deficient
and ARID1A-intact
advanced solid
tumor
malignancies
Lindemann, Olaparib Abstract #740PePoster
K maintenance
monotherapy for
non-germline
BRCA1/2-mutated
(non-gBRCAm)
platinum
-sensitive
relapsed ovarian
cancer (PSR OC):
exploratory
biomarker
analyses of the
Phase IIIb
OPINION study
Sabatier, Efficacy and Abstract #739PePoster
R safety of
maintenance
olaparib and
bevacizumab (bev)
in ovarian cancer
(OC) patients
(pts)aged ≥65
years (y) from
the PAOLA-1/ENGOT
-ov25 first-line
trial
Schweizer, Bipolar Androgen Abstract #592PePoster
MT Therapy (BAT)
plus Olaparib in
Men with
Metastatic
Castration
-resistant
Prostate Cancer
(mCRPC)

[1] 88 abstracts at ESMO Congress 2021 will feature AstraZeneca medicines and pipeline molecules.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).